REVIEW PAPER
Pathogenesis and treatment of irritable bowel syndrome
1
Department of Food and Nutrition, Medical University of Lublin, Poland
2
Department of Dietetics and Nutrition Education, Medical University of Lublin, Poland
Submission date: 2024-04-09
Final revision date: 2024-05-17
Acceptance date: 2024-10-03
Publication date: 2025-09-17
Corresponding author
Wojciech Koch
Wojciech Koch Department of Food and Nutrition Medical University of Lublin 4a Chodzki, 20-093 Lublin, Poland
Wojciech Koch Department of Food and Nutrition Medical University of Lublin 4a Chodzki, 20-093 Lublin, Poland
Medical Studies 2025;41(3):179-188
KEYWORDS
irritable bowel syndrome (IBS)pathogenesis of IBSbrain-gut-microbiome axismicrobiotatreatment of IBS
TOPICS
ABSTRACT
Irritable bowel syndrome (IBS), characterized as a functional gastrointestinal disorder, manifests with recurrent abdominal pain and bowel movement issues. The pathogenesis of IBS is a complex process involving factors such as genetics, composition of gut microbiota, previous infections, and environmental factors. Recent studies indicate that gut dysbiosis, caused by chronic inflammation, may damage the intestinal barrier by activating mast cells at the molecular level. The increased quantity of these cells can lead to disrupted communication on the gut-brain axis, consequently induce the development of general pro-inflammatory phenotype and contribute to the development of post-infectious IBS (PI-IBS). Despite progress in understanding the mechanisms, further research is needed to fully comprehend the pathophysiology of IBS. Current therapeutic approaches focus on individualized treatment, encompassing lifestyle changes, cognitive-behavioral therapies, pharmacotherapy, and probiotic therapy.
REFERENCES (73)
1.
Zhu S, Liu S, Li H, Zhang Z, Zhang Q, Chen L, Zhao Y, Chen Y, Gu J, Min L, Zhang S. Identification of gut microbiota and metabolites signature in patients with irritable bowel syndrome. Front Cell Infect Microbiol. 2019; 9: 346.
2.
Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015; 313(9): 949-958.
3.
Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020; 17(8): 473-486.
4.
Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5(10): 908-917.
5.
Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil. 2017; 23: 151-163.
6.
Oświęcimska J, Szymlak A, Roczniak W, Girczys-Połedniok K, Kwiecień J. New insights into the pathogenesis and treatment of irritable bowel syndrome. Adv Med Sci. 2017; 62: 17-30.
7.
El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol. 2012; 18: 5151-5163.
8.
Mittal A, Gupta S, Afridi F, Dimitrey A, Ahlawat S. Do socio-demographics play a role in the prevalence of red flags and pursuant colonoscopies in patients with irritable bowel syndrome? Cureus. 2022; 14(5): e25137.
9.
Defrees DN, Bailey J. Irritable bowel syndrome: epidemiology, pathophysiology, diagnosis, and treatment. Prim Care. 2017; 44(4): 655-671.
10.
Camilleri M. Diagnosis and treatment of irritable bowel syndrome: a review. JAMA. 2021; 325(9): 865-877.
11.
Hillestad EMR, van der Meeren A, Nagaraja BH, Bjørsvik BR, Haleem N, Benitez-Paez A, Sanz Y, Hausken T, Lied GA, Lundervold A, Berentsen B. Gut bless you: the microbiota- gut-brain axis in irritable bowel syndrome. World J Gastroenterol. 2022; 28(4): 412-431.
12.
Galica AN, Galica R, Dumitrașcu DL. Diet, fibers, and probiotics for irritable bowel syndrome. J Med Life. 2022; 15(2): 174-179.
13.
Radovanovic-Dinic B, Tesic-Rajkovic S, Grgov S, Petrovic G, Zivkovic V. Irritable bowel syndrome – from etiopathogenesis to therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018; 162(1): 1-9.
14.
Rola mikrobioty jelitowej w zespole jelita nadwrażliwego Postępy Higieny [Internet]. [cytowane 12 styczeń 2024]. Dostępne na: https://phmd.pl/resources/html....
15.
Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020; 396(10263): 1675-1688.
16.
Margolis KG, Cryan JF, Mayer EA. The microbiota-gut-brain axis: from motility to mood. Gastroenterology. 2021; 160(5): 1486-1501.
17.
Frankiensztajn LM, Elliott E, Koren O. The microbiota and the hypothalamus-pituitary-adrenocortical (HPA) axis, implications for anxiety and stress disorders. Curr Opin Neurobiol. 2020; 62: 76-82.
18.
Mahurkar-Joshi S, Chang L. Epigenetic mechanisms in irritable bowel syndrome. Front Psychiatry. 2020; 11: 805.
19.
Orock A, Louwies T, Ligon CO, Mohammadi E, Greenwood-Van Meerveld B. Environmental enrichment prevents stress-induced epigenetic changes in the expression of glucocorticoid receptor and corticotrophin releasing hormone in the central nucleus of the amygdala to inhibit visceral hypersensitivity. Exp Neurol. 2021; 345: 113841.
20.
Pellissier S, Bonaz B. The place of stress and emotions in the irritable bowel syndrome. Vitam Horm. 2017; 103: 327-354.
21.
Louwies T, Ligon CO, Johnson AC, Greenwood-Van Meerveld B. Targeting epigenetic mechanisms for chronic visceral pain: a valid approach for the development of novel therapeutics. Neurogastroenterol Motil. 2019; 31(3): e13500.
22.
Videlock EJ, Shih W, Adeyemo M, Mahurkar-Joshi S, Presson AP, Polytarchou C, Alberto M, Iliopoulos D, Mayer EA, Chang L. The effect of sex and irritable bowel syndrome on HPA axis response and peripheral glucocorticoid receptor expression. Psychoneuroendocrinology. 2016; 69: 67-76.
23.
Schaper SJ, Stengel A. Emotional stress responsivity of patients with IBS – a systematic review. J Psychosom Res. 2022; 153: 110694.
24.
Guleria A, Karyampudi A, Singh R, Khetrapal CL, Verma A, Ghoshal UC, Kumar D. Mapping of brain activations to rectal balloon distension stimuli in male patients with irritable bowel syndrome using functional magnetic resonance imaging. J Neurogastroenterol Motil. 2017; 23(3): 415-427.
25.
Ancona A, Petito C, Iavarone I, Petito V, Galasso L, Leonetti A, Turchini L, Belella D, Ferrarrese D, Addolora- to G, Armuzzi A, Gasbarrini A, Scaldaferri F. The gut-brain axis in irritable bowel syndrome and inflammatory bowel disease. Dig Liver Dis. 2021; 53(3): 298-305.
26.
Wilson BC, Vatanen T, Cutfield WS, O’Sullivan JM. The super-donor phenomenon in fecal microbiota transplantation. Front Cell Infect Microbiol. 2019; 9: 2.
27.
Chong PP, Chin VK, Looi CY, Wong WF, Madhavan P, Yong VC. The microbiome and irritable bowel syndrome – a review on the pathophysiology, current research and future therapy. Front Microbiol. 2019; 10: 1136.
28.
Suzuki T. Regulation of the intestinal barrier by nutrients: the role of tight junctions. Anim Sci J. 2020; 91(1): e13357.
29.
Mishima Y, Ishihara S. Molecular mechanisms of microbiota-mediated pathology in irritable bowel syndrome. Int J Mol Sci. 2020; 21(22): 8664.
30.
Mihindukulasuriya KA, Mars RAT, Johnson AJ, Ward T, Priya S, Lekatz HR, Kalari KR, Droit L, Zheng T, Blek- hman R, D’Amato M, Farrugia G, Knights D, Handley SA, Kashyap PC. Multi-omics analyses show disease, diet, and transcriptome interactions with the virome. Gastroenterology. 2021; 161(4): 1194-1207.
31.
Pimentel M, Lembo A. Microbiome and its role in irritable bowel syndrome. Dig Dis Sci. 2020; 65(3): 829-839.
32.
Canakis A, Haroon M, Weber HC. Irritable bowel syndrome and gut microbiota. Curr Opin Endocrinol Diabetes Obes. 2020; 27(1): 28-35.
33.
Ng QX, Soh AYS, Loke W, Lim DY, Yeo WS. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res. 2018; 11: 345-349.
34.
Cremon C, Stanghellini V, Barbaro MR, Cogliandro RF, Bellacosa L, Santos J, Vicario M, Pigrau M, Alonso Cotoner C, Lobo B, Azpiroz F, Bruley des Varannes S, Neun- list M, DeFilippis D, Iuvone T, Petrosino S, Di Marzo V, Barbara G. Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Aliment Pharmacol Ther. 2017; 45(7): 909-922.
35.
Sadeghi A, Biglari M, Nasseri Moghaddam S. Post-infectious irritable bowel syndrome: a narrative review. Middle East J Dig Dis. 2019; 11(2): 69-75.
36.
Scallan Walter EJ, Crim SM, Bruce BB, Griffin PM. Postinfectious irritable bowel syndrome after campylobacter infection. Am J Gastroenterol. 2019; 114(10): 1649-1656.
37.
Sundin J, Rangel I, Fuentes S, Heikamp-de Jong I, Hultgren-Hörnquist E, de Vos WM, Brummer RJ. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther. 2015; 41(4): 342-351.
38.
Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Suret- te M, Moayyedi P. Gut microbiota in patients with irritable bowel syndrome-a systematic review. Gastroenterology. 2019; 157(1): 97-108.
39.
Vich Vila A, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A, Bonder MJ, Jiang X, Tigchelaar EF, Dekens J, Peters V, Voskuil MD, Vissche- dijk MC, van Dullemen HM, Keszthelyi D, Swertz MA, Franke L, Alberts R, Festen EAM, Dijkstra G, Masclee AAM, Hofker MH, Xavier RJ, Alm EJ, Fu J, Wijmenga C, Jonkers DMAE, Zhernakova A, Weersma RK. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med. 2018; 10(472): eaap8914.
40.
Mujagic Z, Kasapi M, Jonkers DM, Garcia-Perez I, Vork L, Weerts ZZRM, Serrano-Contreras JI, Zhernakova A, Kurilshikov A, Scotcher J, Holmes E, Wijmenga C, Keszthelyi D, Nicholson JK, Posma JM, Masclee AA. Integrated fecal microbiome-metabolome signatures reflect stress and serotonin metabolism in irritable bowel syndrome. Gut Microbes. 2022; 14(1): 2063016.
41.
Algera JP, Magnusson MK, Öhman L, Störsrud S, Simrén M, Törnblom H. Randomised controlled trial: effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome. Aliment Pharmacol Ther. 2022; 56(9): 1318-1327.
42.
Lenhart A, Dong T, Joshi S, Jaffe N, Choo C, Liu C, Jacobs JP, Lagishetty V, Shih W, Labus JS, Gupta A, Tillisch K, Mayer EA, Chang L. Effect of exclusion diets on symptom severity and the gut microbiota in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2022; 20(3): e465-e483.
43.
Staudacher HM, Scholz M, Lomer MCe, Ralph FS, Irving PM, Lindsay JO, Fava F, Tuohy K, Whelan K. Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics. Clin Nutr. 2021; 40(4): 1861-1870.
44.
Ostgaard H, Hausken T, Gundersen D, El-Salhy M. Diet and effects of diet management on quality of life and symptoms in patients with irritable bowel syndrome. Mol Med Rep. 2012; 5(6): 1382-1390.
45.
El-Salhy M, Hatlebakk JG, Hausken T. Diet in irritable bowel syndrome (IBS): interaction with gut microbiota and gut hormones. Nutrients. 2019; 11(8): 1824.
46.
Cozma-Petruţ A, Loghin F, Miere D, Dumitraşcu DL. Diet in irritable bowel syndrome: what to recommend, not what to forbid to patients! World J Gastroenterol. 2017; 23(21): 3771-3783.
47.
Pietrzak A, Skrzydło-Radomańska B, Mulak A, Lipiński M, Małecka-Panas E, Reguła J, Rydzewska G. Guidelines on the management of irritable bowel syndrome. Gastroenterology Rev. 2018; 13(4): 259-288.
48.
National Collaborating Centre for Nursing and Supportive Care (UK). Irritable Bowel Syndrome in Adults: Diagnosis and Management of Irritable Bowel Syndrome in Primary Care [Internet]. London: Royal College of Nursing (UK); 2008 [CIted 15 January 2024]. (National Institute for Health and Clinical Excellence: Guidance). Available at: http://www.ncbi.nlm.nih.gov/bo....
49.
Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, Agrawal A, Aziz I, Farmer AD, Eugenicos MP, Moss-Morris R, Yiannakou Y, Ford AC. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021; 70(7): 1214-1240.
50.
Colomier E, Van Oudenhove L, Tack J, Böhn L, Bennet S, Nybacka S, Störsrud S, Öhman L, Törnblom H, Simrén M. Predictors of symptom-specific treatment response to dietary interventions in irritable bowel syndrome. Nutrients. 2022; 14(2): 397.
51.
Bellini M, Tonarelli S, Nagy AG, Pancetti A, Costa F, Ricchiuti A, de Bortoli N, Mosca M, Marchi S, Rossi A. Low FODMAP diet: evidence, doubts, and hopes. Nutrients. 2020; 12(1): 148.
52.
Spiller R. How do FODMAPs work? J Gastroenterol Hepatol. 2017; 32 Suppl 1: 36-39.
53.
Manning LP, Yao CK, Biesiekierski JR. Therapy of IBS: is a low FODMAP diet the answer? Front Psychiatry. 2020; 11: 865.
54.
Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2022; 71(6): 1117-1126.
55.
Barrett JS. How to institute the low-FODMAP diet. J Gastroenterol Hepatol. 2017; 32 Suppl 1: 8-10.
56.
Altomare A, Di Rosa C, Imperia E, Emerenziani S, Cicala M, Guarino MPL. Diarrhea predominant-irritable bowel syndrome (IBS-D): effects of different nutritional patterns on intestinal dysbiosis and symptoms. Nutrients. 2021; 13(5): 1506.
57.
Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol. 2019; 114(1): 21-39.
58.
Sugaya N, Shirotsuki K, Nakao M. Cognitive behavioral treatment for irritable bowel syndrome: a recent literature review. BioPsychoSocial Medicine. 2021; 15(1): 23.
59.
Black CJ, Burr NE, Camilleri M, Earnest DL, Quigley EM, Moayyedi P, Houghton LA, Ford AC. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut. 2020; 69(1): 74-82.
60.
Jacobs JP, Gupta A, Bhatt RR, Brawer J, Gao K, Tillisch K, Lagishetty V, Firth R, Gudleski GD, Ellingson BM, Labus JS, Naliboff BD, Lackner JM, Mayer EA. Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome. 2021; 9(1): 236.
61.
Lackner JM, Jaccard J, Keefer L, Brenner DM, Firth RS, Gudleski GD, Hamilton FA, Katz LA, Krasner SA, Ma CX, Radziwon CD, Sitrin MD. Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome. Gastroenterology. 2018; 155(1): 47-57.
62.
Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018; 48(10): 1044-1060.
63.
Jeong B, Sung TS, Jeon D, Park KJ, Jun JY, So I, Hong C. Inhibition of TRPC4 channel activity in colonic myocytes by tricyclic antidepressants disrupts colonic motility causing constipation. J Cell Mol Med. 2022; 26(19): 4911-4923.
64.
Ford AC, Wright-Hughes A, Alderson SL, Ow PL, Ridd MJ, Foy R, Bianco G, Bishop FL, Chaddock M, Cook H, Cooper D, Fernandez C, Guthrie EA, Hartley S, Herbert A, Howdon D, Muir DP, Nath T, Newman S, Smith T, Taylor CA, Teasdale EJ, Thornton R, Farrin AJ, Everitt HA; ATLANTIS trialists. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 402(10414): 1773-1785.
65.
Salvioli B. Trimebutine: a state-of-the-art review. Minerva Gastroenterol Dietol. 2019; 65(3): 229-238.
66.
Saps M, Miranda A. Gastrointestinal Pharmacology. In: Handbook of Experimental Pharmacology. 2017. Available at: https://www.semanticscholar.or....
67.
Makarova AA, Diukova GM, Ruchkina IN, Romashkina NV, Indejkina LK, Degterev DA, Dbar SR, Parfenov AI. [Visceral sensitivity in diagnostics and treatment of severe irritated bowel syndrome]. Ter Arkh. 2022; 94(2S): 356-361.
68.
Black CJ, Ford AC. Best management of irritable bowel syndrome. Frontline Gastroenterol. 2021; 12(4): 303-315.
69.
Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017; 66(5): 966-974.
70.
Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009; 18(3): 349-358.
71.
Nelson AD, Black CJ, Houghton LA, Lugo-Fagundo NS, Lacy BE, Ford AC. Systematic review and network meta- analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2021; 54(2): 98-108.
72.
Xie CR, Tang B, Shi YZ, Peng WY, Ye K, Tao QF, Yu SG, Zheng H, Chen M. Low FODMAP diet and probiotics in irritable bowel syndrome: a systematic review with network meta-analysis. Front Pharmacol. 2022; 13: 853011.
73.
Dale HF, Rasmussen SH, Asiller ÖÖ, Lied GA. Probiotics in irritable bowel syndrome: an up-to-date systematic review. Nutrients. 2019; 11(9): 2048.
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
